Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The conformation of this loop is virtually identical in the three HDLP structures (Finnin et al., 1999), suggesting that the surface of HDLP is less malleable than that of HDAC8 around the binding site pocket.”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“The apparent reduced flexibility in the HDLP surface may also explain why it is less efficient in histone deacetylase assays (Finnin et al., 1999).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“Finnin et al. (1999) have suggested that H143 protonates the lysine after the carbon-nitrogen scissile bond breaks.”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Finnin et al., 1999
In the citing paper
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Finnin et al., 1999
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures
Kraulis, P. J. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891004399 · Cited by 14,085
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
[26] Raster3D: Photorealistic molecular graphics
Merritt, E. A., & Bacon, D. J. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)77028-9 · Cited by 3,739
The relation between the divergence of sequence and structure in proteins.
Chothia, C., & Lesk, A. M. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04288.x · Cited by 2,458
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815
The complete genome of the hyperthermophilic bacterium Aquifex aeolicus
Deckert, G., Warren, P. V., Gaasterland, T., Young, W. G., Lenox, A. L., Graham, D. E., Overbeek, R., Snead, M. A., Keller, M., Aujay, M., et al. (1998) · Nature · doi:10.1038/32831 · Cited by 1,097
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citation
Research works printed but not linked: 2
- Cohen,L. A. et al. Inhibition of N-methylnitrosourea-induced tumours by the cytodifferentiating agent, suberanilohydroxamic acid (SAHA). Proc. AACR 39, 108, abstr. 736 (1998).
- Desai,D., El-Bayoumy,K. & Amin,S. Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylinitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Proc. AACR 40, 2396, abstr. 362 (1999).
Cited by
Items 301–400 of 1,007
Histone Deacetylase Inhibitors: Biology and Mechanism of Action
Mehnert, J. M., & Kelly, W. K. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31803c72ba · Cited by 124
Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy
Zheng, Y. G., Wu, J., Chen, Z., & Goodman, M. (2008) · Medicinal Research Reviews · doi:10.1002/med.20120 · Cited by 123
Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors
Osada, S., Sano, S., Ueyama, M., Chuman, Y., Kodama, H., & Sakaguchi, K. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.005 · Cited by 122
HDAC inhibitors: a potential new category of anti-tumor agents.
Li, P., Lu, J., & Huang, B. (2007) · PubMed · Cited by 121
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)
Curtin, M. L., Garland, R. B., Heyman, H. R., Frey, R. R., Michaelides, M. R., Li, J., Pease, L. J., Glaser, K. B., Marcotte, P. A., & Davidsen, S. K. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00622-4 · Cited by 121
Zhou, X., Richon, V. M., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1056 · Cited by 120
Self-citationLi, G., Yao, W., & Jiang, H. (2014) · Journal of Nutrition · doi:10.3945/jn.114.198531 · Cited by 120
SU(VAR)3-9 is a Conserved Key Function in Heterochromatic Gene Silencing
Schotta, G., Ebert, A., & Reuter, G. (2003) · Genetica · doi:10.1023/a:1022923508198 · Cited by 119
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors
Venturelli, S., Belz, R. G., Kämper, A., Berger, A., von Horn, K., Wegner, A., Böcker, A., Zabulon, G., Langenecker, T., Kohlbacher, O., et al. (2015) · The Plant Cell · doi:10.1105/tpc.15.00585 · Cited by 118
Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor
Rubio‐Ruíz, B., Weiss, J. T., & Unciti‐Broceta, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01426 · Cited by 118
Histone deacetylases as therapeutic targets in hematologic malignancies
Melnick, A., & Licht, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00010 · Cited by 117
Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A
Codd, R., Braich, N., Liu, J., Soe, C. Z., & Pakchung, A. A. H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.05.026 · Cited by 117
The Design of Inhibitors for Medicinally Relevant Metalloproteins
Jacobsen, F. E., Lewis, J. A., & Cohen, S. M. (2007) · ChemInform · doi:10.1002/chin.200719261 · Cited by 117
Lü, Q., Yang, Y., Chen, C., Davis, M. E., Byrd, J. C., Etherton, M. R., Umar, A., & Chen, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303655 · Cited by 117
Rajak, H., Agarawal, A., Parmar, P., Thakur, B. S., Veerasamy, R., Sharma, P. C., & Kharya, M. D. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.022 · Cited by 117
Annunziata, I., van de Vlekkert, D., Wolf, E., Finkelstein, D., Neale, G., Machado, E., Mosca, R., Campos, Y., Tillman, H., Roussel, M. F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11568-0 · Cited by 115
Targeting Histone Deacetylases as a Multifaceted Approach to Treat the Diverse Outcomes of Stroke
Langley, B., Brochier, C., & Rivieccio, M. A. (2009) · Stroke · doi:10.1161/strokeaha.108.540229 · Cited by 115
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases
JONES, P. G., Altamura, S., Francesco, R. D., Gallinari, P., Lahm, A., Neddermann, P., Rowley, M., Serafini, S., & Steinkühler, C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.025 · Cited by 115
Chemical and structural biology of protein lysine deacetylases
Yoshida, M., Kudo, N., Kosono, S., & Ito, A. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.019 · Cited by 115
Potent Antimalarial Activity of Histone Deacetylase Inhibitor Analogues
Andrews, K. T., Tran, T. N., Lucke, A. J., Kahnberg, P., Le, G. T., Boyle, G. M., Gardiner, D. L., Skinner-Adams, T. S., & Fairlie, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00757-07 · Cited by 115
Targeting epigenetic enzymes for drug discovery
Copeland, R. A., Olhava, E. J., & Scott, M. P. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.174 · Cited by 115
Chen, P. C., Patil, V., Guerrant, W., Green, P., & Oyelere, A. K. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.050 · Cited by 114
Abdizadeh, T., Kalani, M. R., Abnous, K., Tayarani‐Najaran, Z., Khashyarmanesh, B. Z., Abdizadeh, R., Ghodsi, R., & Hadizadeh, F. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.024 · Cited by 114
The molecular mechanism of HDAC inhibitors in anticancer effects.
Bi, G., & Jiang, G. (2006) · PubMed · Cited by 114
Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer
Peng, L., & Seto, E. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_3 · Cited by 113
Senger, J., Melesina, J., Marek, M., Romier, C., Oehme, I., Witt, O., Sippl, W., & Jung, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01493 · Cited by 112
Biomarkers for predicting clinical responses to HDAC inhibitors
Stimson, L., & Thangue, N. B. L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.016 · Cited by 112
Dietary agents as histone deacetylase inhibitors
Myzak, M. C., Ho, E., & Dashwood, R. H. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20224 · Cited by 112
Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor
Poux, A. N., Cebrat, M., Kim, C. M., Cole, P. A., & Marmorstein, R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222373899 · Cited by 111
Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate
Sekhavat, A., Sun, J.-M., & Davie, J. R. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-145 · Cited by 110
Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors
Estiu, G., Greenberg, E., Harrison, C. B., Kwiatkowski, N. P., Mazitschek, R., Bradner, J. E., & Wiest, O. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015254 · Cited by 110
Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Wagner, F. F., Weïwer, M., Lewis, M. C., & Holson, E. B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0226-1 · Cited by 110
Suzuki, T., Nagano, Y., Kouketsu, A., Matsuura, A., Maruyama, S., Kurotaki, M., Nakagawa, H., & Miyata, N. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049207j · Cited by 109
Tang, H., Wang, X. S., Huang, X., Roth, B. L., Butler, K. V., Kozikowski, A. P., Jung, M., & Tropsha, A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800366f · Cited by 109
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602047 · Cited by 109
Reilly, C. M., Thomas, M. R., Gogal, R. M., Olgun, S., Santo, A., Sodhi, R., Samy, E. T., Peng, S. L., Gilkeson, G. S., & Mishra, N. (2008) · Journal of Autoimmunity · doi:10.1016/j.jaut.2008.04.020 · Cited by 109
Rodrigues, D. A., Ferreira-Silva, G. À., Ferreira, A. C. S., Fernandes, R. A., Kwee, J. K., Sant’Anna, C. M. R., Ionta, M., & Fraga, C. A. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01525 · Cited by 109
Zhang, Q., Zeng, S. X., Zhang, Y., Zhang, Y., Ding, D., Ye, Q., Meroueh, S. O., & Lu, H. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100211 · Cited by 109
Stathis, A., Hotte, S. J., Chen, E. X., Hirte, H. W., Oza, A. M., Moretto, P., Webster, S., Laughlin, A., Stayner, L.-A., McGill, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1893 · Cited by 108
Corminboeuf, C., Hu, P., Tuckerman, M. E., & Zhang, Y. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0600882 · Cited by 107
Epigenetic Regulation of Opioid-Induced Hyperalgesia, Dependence, and Tolerance in Mice
Liang, D., Li, X., & Clark, J. D. (2012) · Journal of Pain · doi:10.1016/j.jpain.2012.10.005 · Cited by 106
Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets
Javaid, N., & Choi, S. (2017) · Genes · doi:10.3390/genes8080196 · Cited by 106
Zhou, Q., Melkoumian, Z. K., Lucktong, A., Moniwa, M., Davie, J. R., & Strobl, J. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003106200 · Cited by 105
Lauria, A., Monica, G. L., Bono, A., & Martorana, A. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113555 · Cited by 105
Mai, A., Massa, S., Ragno, R., Cerbara, I., Jesacher, F., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021070e · Cited by 104
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
Khan, O. A., & Thangue, N. B. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1238 · Cited by 104
Histone acetylation and the cell-cycle in cancer
Wang, C. (2001) · Frontiers in Bioscience · doi:10.2741/1wang1 · Cited by 103
Thiol-based SAHA analogues as potent histone deacetylase inhibitors
Suzuki, T., Kouketsu, A., Matsuura, A., Kohara, A., Ninomiya, S.-I., Kohda, K., & Miyata, N. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.063 · Cited by 103
Acetylation of proteins as novel target for antitumor therapy: Review article
Gennaro, E. D., Bruzzese, F., Caraglia, M., Abruzzese, A., & Budillon, A. (2004) · Amino Acids · doi:10.1007/s00726-004-0087-3 · Cited by 103
Chromatin, cancer and drug therapies
Cortez, C. C., & Jones, P. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.006 · Cited by 103
Hrzenjak, A., Kremser, M., Strohmeier, B., Moinfar, F., Zatloukal, K., & Denk, H. (2008) · The Journal of Pathology · doi:10.1002/path.2434 · Cited by 101
Mahboobi, S., Dove, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T. M., & Beckers, T. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800988r · Cited by 101
Baud, M. G. J., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016182 · Cited by 100
Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity
Haggarty, S. J., & Tsai, L.-H. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.04.009 · Cited by 100
Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors
Lu, Q., Wang, D.-S., Chen, C.-S., Hu, Y.-D., & Chen, C.-S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503749 · Cited by 100
Weston, C. E., Krämer, A., Colin, F., Yıldız, Ö., Baud, M. G. J., Meyer‐Almes, F., & Fuchter, M. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00148 · Cited by 100
Huang, H., Liu, N., Guo, H., Liao, S., Li, X., Yang, C., Liu, S., Song, W., Liu, C., Guan, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049062 · Cited by 99
Targeting histone deacetylases for the treatment of cancer and inflammatory diseases
Huang, L. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20781 · Cited by 98
Hos1 Is a Lysine Deacetylase for the Smc3 Subunit of Cohesin
Xiong, B., Lu, S., & Gerton, J. L. (2010) · Current Biology · doi:10.1016/j.cub.2010.08.019 · Cited by 98
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 98
Copper‐Catalyzed 1,2‐Addition of α‐Carbonyl Iodides to Alkynes
Xu, T., & Hu, X. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201410279 · Cited by 98
Structure of Histone Deacetylases
Marmorstein, R. (2001) · Structure · doi:10.1016/s0969-2126(01)00690-6 · Cited by 97
Regulation of BRCA2 Gene Expression by the SLUG Repressor Protein in Human Breast Cells
Tripathi, M. K., Misra, S., Khedkar, S. V., Hamilton, N. M., Irvin-Wilson, C. V., Sharan, C., Sealy, L. J., & Chaudhuri, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501375200 · Cited by 97
Richon, V. M., Zhou, X., Rifkind, R. A., & Marks, P. A. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0376 · Cited by 97
Self-citationLee, J.-I., Nian, H., Cooper, A. J. L., Sinha, R., Dai, J., Bisson, W. H., Dashwood, R. H., & Pinto, J. T. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0047 · Cited by 97
Patel, V., Mazitschek, R., Coleman, B. I., Nguyen, C., Urgaonkar, S., Cortese, J. F., Barker, R. H., Greenberg, E. F., Tang, W., Bradner, J. E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801654y · Cited by 97
Pan, L., Matloob, A. F., Du, J., Pan, H., Dong, Z., Zhao, J., Feng, Y., Zhong, Y., Huang, B., & Lu, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07542.x · Cited by 97
Gonzalez-Zuñiga, M., Contreras, P. S., Estrada, L. D., Chamorro, D., Villagra, A., Zanlungo, S., Seto, E., & Alvarez, A. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.013 · Cited by 96
Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939
Sumanadasa, S. D. M., Goodman, C. D., Lucke, A. J., Skinner‐Adams, T. S., Sahama, I., Haque, A., Do, T. A., McFadden, G. I., Fairlie, D. P., & Andrews, K. T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-12 · Cited by 96
Histone deacetylases: Focus on the nervous system
Morrison, B. E., Majdzadeh, N., & D’Mello, S. R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7035-9 · Cited by 95
Hrzenjak, A., Moinfar, F., Kremser, M., Strohmeier, B., Petru, E., Zatloukal, K., & Denk, H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-49 · Cited by 95
Histone modification enzymes: novel targets for cancer drugs
Kristeleit, R. S., Stimson, L., Workman, P., & Aherne, W. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.135 · Cited by 95
Li, H., Torres-Garcia, S., Latrasse, D., Benhamed, M., Schilderink, S., Zhou, W., Kulikova, O., Hirt, H., & Bisseling, T. (2017) · The Plant Cell · doi:10.1105/tpc.17.00366 · Cited by 95
Wang, Q., Kawahara, T., & Horn, D. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07284.x · Cited by 95
Fournel, M., Trachy-Bourget, M.-C., Yan, P. T., Kalita, A., Bonfils, C., Beaulieu, C., Fréchette, S., Leit, S. M., Abou-Khalil, E., Woo, S.-H., et al. (2002) · PubMed · Cited by 94
Small-molecule microarrays as tools in ligand discovery
Vegas, A. J., Fuller, J. H., & Koehler, A. N. (2008) · Chemical Society Reviews · doi:10.1039/b703568n · Cited by 94
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93
α-Keto amides as inhibitors of histone deacetylase
Wada, C. K., Frey, R. R., Ji, Z., Curtin, M. L., Garland, R. B., Holms, J. H., Li, J., Pease, L. J., Guo, J., Glaser, K. B., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00685-1 · Cited by 93
Santos, M. D. L., Zambrano, A., & Aranda, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0623 · Cited by 93
Discovery of histone deacetylase 8 selective inhibitors
Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 92
Modulation of cellular radiation responses by histone deacetylase inhibitors
Karagiannis, T. C., & El‐Osta, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209417 · Cited by 91
Histone Deacetylase Inhibitors through Click Chemistry
Shen, J., Woodward, R., Kedenburg, J., Liu, X., Chen, M., Fang, L., Sun, D., & Wang, P. G. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8005355 · Cited by 91
Souto, J. A., Vaz, E., Lepore, I., Pöppler, A., Franci, G., Álvarez, R., Altucci, L., & de Lera, Á. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100244y · Cited by 91
Pontiki, E. A., & Hadjipavlou‐Litina, D. (2011) · Medicinal Research Reviews · doi:10.1002/med.20200 · Cited by 91
Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer
Mitsiades, C. S., Poulaki, V., McMullan, C. J., Negri, J. M., Fanourakis, G., Goudopoulou, A., Richon, V. M., Marks, P. A., & Mitsiades, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0776 · Cited by 91
Self-citationChen, D., Soh, C. K., Goh, W. H., & Wang, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01465 · Cited by 91
Traisaeng, S., Herr, D. R., Kao, H.-J., Chuang, T., & Huang, C. (2019) · Toxins · doi:10.3390/toxins11060311 · Cited by 91
Histone deacetylase inhibitors: Anticancer compounds
Smith, K. T., & Workman, J. L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.008 · Cited by 90
Sanderson, L., Taylor, G. W., Aboagye, E. O., Alao, J. P., Latigo, J. R., Coombes, R. C., & Vigushin, D. M. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000638 · Cited by 90
“Other than trichostatin A, this was the only structure with an intact hydroxamic acid group, supporting the hypothesis that chelation of zinc at the base of the histone deacetylase enzyme active site by the hydroxamic acid group of trichostatin A prevents binding of the natural acetyl lysine substrate (Finnin et al.,…”
BackgroundJacob, A. L., Lund, J., Martinez, P., & Hedin, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104427200 · Cited by 90
Edderkaoui, M., Chheda, C., Soufi, B., Zayou, F., Hu, R. W., Ramanujan, V. K., Pan, X., Boros, L. G., Tajbakhsh, J., Madhav, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.028 · Cited by 90
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
Cang, S., Ma, Y., & Liu, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-22 · Cited by 90
Deacetylase Inhibitors Dissociate the Histone-Targeting ING2 Subunit from the Sin3 Complex
Smith, K. T., Martin‐Brown, S., Florens, L. A., Washburn, M. P., & Workman, J. L. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.12.010 · Cited by 89
Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity
Maulucci, N., Chini, M. G., Micco, S. D., Izzo, I., Cafaro, E., Russo, A., Gallinari, P., Paolini, C., Nardi, M. C., Casapullo, A., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0686256 · Cited by 89
Strategies in developing promising histone deacetylase inhibitors
Zhang, L., Fang, H., & Xu, W. (2009) · Medicinal Research Reviews · doi:10.1002/med.20169 · Cited by 88
Kinetics and Comparative Reactivity of Human Class I and Class IIb Histone Deacetylases
Schultz, B. E., Misialek, S., Wu, J., Tang, J., Conn, M. T., Tahilramani, R., & Wong, L. (2004) · Biochemistry · doi:10.1021/bi0494471 · Cited by 88
Macrocyclic Histone Deacetylase Inhibitors
C. Mwakwari, S., Patil, V., Guerrant, W., & K. Oyelere, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610792232079 · Cited by 88
Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators
Klein, M. A., & Denu, J. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011438 · Cited by 88
Griffith, D. M., Szőcs, B., Keogh, T., Suponitsky, K. Y., Farkas, E., Buglyó, P., & Marmion, C. J. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.03.003 · Cited by 88
Metadata
- Authors
- Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Pavletich, Nikola P.
- Venue
- Nature
- Published
- 1999-09
- Volume
- 401
- Issue
- 6749
- Pages
- 188-193
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2135830745
- Cited by
- 1,714
- References
- 28
- Citations by year
- 2026: 39 · 2025: 48 · 2024: 40 · 2023: 55 · 2022: 28 · 2021: 66 · 2020: 62 · 2019: 50 · 2018: 52 · 2017: 70 · 2016: 68 · 2015: 74 · 2014: 67 · 2013: 78 · 2012: 82
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, trichostatin A, vorinostat, Aquifex aeolicus, crystal structure, catalytic site, zinc binding site, hyperthermophilic bacteria, anticancer agents, promyelocytic leukemia
- MeSH terms
- Vorinostat, Amino Acid Sequence, Enzyme Inhibitors, Escherichia coli, Histone Deacetylases, Humans, Hydroxamic Acids, Models, Molecular, Molecular Sequence Data, Protein Binding, Protein Conformation, Recombinant Fusion Proteins, Zinc, Gram-Negative Aerobic Rods and Cocci, Sequence Homology, Amino Acid, Crystallography, X-Ray, Catalytic Domain, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.